Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination

Robert A Watson,Weiyu Ye,Chelsea A Taylor,Elsita Jungkurth,Rosalin Cooper,Orion Tong,Tim James,Brian Shine,Monika Hofer,Damian Jenkins,Robert Pell,Eleni Ieremia,Stephanie Jones,David Maldonado-Perez,Ian S D Roberts,Nicholas Coupe,Mark R Middleton,Miranda J Payne,Benjamin P Fairfax
DOI: https://doi.org/10.1136/jitc-2023-008151
IF: 12.469
2024-04-01
Journal for ImmunoTherapy of Cancer
Abstract:We describe three cases of critical acute myositis with myocarditis occurring within 22 days of each other at a single institution, all within 1 month of receiving the initial cycle of the anti-PD-1 drug pembrolizumab. Analysis of T cell receptor repertoires from peripheral blood and tissues revealed a high degree of clonal expansion and public clones between cases, with several T cell clones expanded within the skeletal muscle putatively recognizing viral epitopes. All patients had recently received a COVID-19 mRNA booster vaccine prior to treatment and were positive for SARS-CoV2 Spike antibody. In conclusion, we report a series of unusually severe myositis and myocarditis following PD-1 blockade and the COVID-19 mRNA vaccination.
oncology,immunology
What problem does this paper attempt to address?